Clinical Trial News and Research

RSS

Researchers publish first detailed figures that show risk of Rasilez and ACE inhibitors or ARBs

Researchers at St. Michael's Hospital have published the first detailed figures showing the risk of using the prescription drug Rasilez in combination with certain other blood pressure-lowering medications.

13 Jan 2012

Cabazitaxel with IMRT, androgen deprivation therapy may extend survival for prostate cancer patients

Jefferson's Kimmel Cancer Center has started a Phase I clinical trial investigating the latest prostate cancer chemotherapy drug to extend survival, Cabazitaxel, in combination with radiation and hormone therapy. This first-of-its-kind multimodality approach could improve disease control and eventually survival for locally advanced prostate cancer patients.

13 Jan 2012

Processed nerve allograft effective in treating PNI

In the first-ever multicenter clinical trial on processed nerve allograft, researchers from The Buncke Clinic in San Francisco found that treatment of severed peripheral nerve with processed nerve allograft showed meaningful recovery in 87 percent of patients, comparing favorably to traditional nerve repair.

13 Jan 2012

Clinical trial to compare Aria's prenatal test and standard first-trimester screening for T21

Aria Diagnostics, a molecular diagnostics company, announced that it is initiating a blinded, multicenter clinical trial that compares its non-invasive prenatal test with the standard first-trimester screening test (serum screening and nuchal translucency ultrasound alone and in combination) to detect Trisomy 21, which is associated with Down syndrome.

13 Jan 2012

SAA protein plays a key role in chronic inflammation and lung damage in COPD

Sufferers of smoking related lung diseases could have their debilitating symptoms reduced following the discovery of a potential new treatment.

13 Jan 2012

Sangart commences MP4CO Phase 1b study in sickle cell disease

Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen and other gas delivery, today announced the initiation of a Phase 1b study designed to evaluate the safety of MP4CO treatment in patients with sickle cell disease.

12 Jan 2012

Aerocrine's NIOX MINO receives market approvals in Taiwan, South Korea

Aerocrine announced that it's product, NIOX MINO, has received market approvals on the South Korean and Taiwanese markets. An approval is an important step towards receiving reimbursement for inflammation monitoring with the help of FeNO in asthma management.

12 Jan 2012

Emboshield Pro safer in patients ineligible for standard surgical treatment of CAD

Placing a stent in a key artery in the neck is safer than ever in patients ineligible for the standard surgical treatment of carotid artery disease, according to a new study published online today in the Journal of Vascular Surgery.

12 Jan 2012

Study confirms condom use reduces risk of HIV infection by 78%

The level of HIV-1 in the blood of an HIV-infected partner is the single most important factor influencing risk of sexual transmission to an uninfected partner, according to a multinational study of heterosexual couples in sub-Saharan Africa.

12 Jan 2012

Spherix completes SPX-106 28-day rat toxicology study

Spherix Incorporated – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today reported the successful completion of its 28-day rat toxicology study of its drug candidate, SPX-106.

11 Jan 2012

$Merrimack commences MM-151 Phase 1 trial in refractory advanced solid tumors$

Merrimack commences MM-151 Phase 1 trial in refractory advanced solid tumors

Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor.

11 Jan 2012

Collaborative behavioral management may be effective in reducing abuse among paroled marijuana users

A study from Rhode Island Hospital has found that collaborative behavioral management may be effective in reducing substance abuse among convicted marijuana users who are paroled. The findings have important implications for the management of a substantial proportion of the U.S. community correctional population.

11 Jan 2012

Health Affairs assesses real-world lifestyle interventions to help prevent diabetes

An Emory University study published in the January issue of Health Affairs assesses real-world lifestyle interventions to help delay or prevent the costly chronic disease that affects nearly 26 million Americans.

11 Jan 2012

Inherited breast and ovarian cancer drug trial re-launched in tablet form

Cancer Research UK's Drug Development Office has re-launched a trial of a promising drug to treat inherited breast and ovarian cancer - but this time taken as a tablet by outpatients.

11 Jan 2012

Nicotine patch may help those with mild dementia

The nicotine patch designed to help people quit smoking can also improve memory in older adults with mild cognitive impairment, or MCI, a small clinical trial found.

10 Jan 2012

Telormedix raises 7.5 million CHF

Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, today announced that it has raised 7.5 Million CHF from existing investors Aravis Venture and Proquest Investments.

10 Jan 2012

JHM, Healthways partner for innovative weight-loss program

Building on the success of recent Hopkins research showing obese participants were able to lose significant weight and keep it off for two years using telephone coaching and a specially designed website, Johns Hopkins Medicine is collaborating with Healthways to help bring the innovative weight-loss program to many more who could benefit from it.

9 Jan 2012

Positive interim data from Idenix IDX184 12-week phase IIb trial on HCV

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced interim data from a 12-week phase IIb clinical trial of IDX184, the Company's lead product candidate for the treatment of hepatitis C virus (HCV) infection.

9 Jan 2012

Idenix Pharmaceuticals makes progress with its HCV development pipeline

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the advancement of its hepatitis C virus development pipeline.

9 Jan 2012

DATATRAK International releases its new product, uCTMS

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the release of its new product, uCTMS.

9 Jan 2012